Skip to Content
Merck
All Photos(1)

Key Documents

SAB4200697

Sigma-Aldrich

Anti-Tyrosine Hydroxylase antibody, Mouse monoclonal

clone TH-16, purified from hybridoma cell culture

Synonym(s):

TH, TYH

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12352203
NACRES:
NA.44

biological source

mouse

Quality Level

antibody form

purified immunoglobulin

antibody product type

primary antibodies

clone

TH-16, monoclonal

form

buffered aqueous solution

species reactivity

rat, dog, rabbit, human, sheep, guinea pig, mouse, monkey, bovine

concentration

~1 mg/mL

technique(s)

immunoblotting: 1-2 μg/mL using whole extract of rat PC-12 cells
immunohistochemistry: suitable
immunoprecipitation (IP): suitable

isotype

IgG1

shipped in

dry ice

storage temp.

−20°C

target post-translational modification

unmodified

Gene Information

human ... TH(7054)

General description

Monoclonal Anti-tyrosine hydroxylase (mouse IgG1 isotype) is derived from the hybridoma TH-16 produced by the fusion of mouse myeloma cells and splenocytes from BALB/c mice immunized with purified rat tyrosine hydroxylase. This antibody recognizes an epitope located in the N-terminal region of human, monkey, bovine, sheep, rabbit, dog, guinea pig, mouse and rat tyrosine hydroxylase (TH).
Tyrosine hydroxylase (TH) is encoded by the gene mapped to human chromosome 11p15. TH is a tetramer of four identical subunits, which is characterized with a regulatory, catalytic, and tetramerization domains. The enzyme utilizes tyrosine, BH4 and O2 as co-substrates, and Fe2+ as a cofactor.

Immunogen

purified rat Tyrosine Hydroxylase

Biochem/physiol Actions

Tyrosine hydroxylase (TH) catalyzes the first rate limiting step in the biosynthesis of catecholamine neurotransmitter,that is, the conversion of L-tyrosine to L-dopa. Inhibition of TH by L-phenylalanine, might play a crucial role in phenylketonuria and block the synthesis of norepinephrine. Activity of TH can be regulated by phosphorylation. Decreased expression of TH is associated with various neuro-psychiatric diseases such as schizophrenia and Parkinson′s disease (PD).

Physical form

Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.

Storage and Stability

For continuous use, store at 2–8°C for up to one month. For extended storage, freeze in working aliquots. Repeated freezing and thawing is not recommended. If slight turbidity occurs upon prolonged storage, clarify the solution by centrifugation. Working dilution samples should be discarded if not used within 12 hours.

Other Notes

In order to obtain best results in different techniques and preparations we recommend determining optimal working concentration by titration test.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Product Selector Tool.

Storage Class Code

10 - Combustible liquids

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Chun Chen et al.
NPJ Parkinson's disease, 7(1), 39-39 (2021-05-14)
Here we report the application of a mass spectrometry-based technology, imaging mass cytometry, to perform in-depth proteomic profiling of mitochondrial complexes in single neurons, using metal-conjugated antibodies to label post-mortem human midbrain sections. Mitochondrial dysfunction, particularly deficiency in complex I
Chang Chen et al.
Metabolic brain disease, 34(1), 203-212 (2018-11-15)
Parkinson's disease (PD) is a common chronic neurodegenerative disease and greatly affects the quality of PD patients' life. Current symptomatic treatment of PD is limited. There are no effective treatment and drugs that could radically cure PD. Increasing experimental evidence
TYROSINE HYDROXYLASE. THE INITIAL STEP IN NOREPINEPHRINE BIOSYNTHESIS.
NAGATSU T, et al.
The Journal of Biological Chemistry, 2910-2917 (1964)
Role of N-terminus of tyrosine hydroxylase in the biosynthesis of catecholamines.
Nakashima A, et al.
Journal of neural transmission (Vienna, Austria : 1996), 116, 1355-1362 (2009)
Guoxue Zhu et al.
Aging, 13(15), 19510-19528 (2021-08-03)
Parkinson's disease (PD), the typical neurodegenerative disease, is characterized by the progressive loss of dopaminergic neurons in the substantia nigra (SN). However, no therapeutic agent used currently could slow down neuronal cell loss so as to decelerate or halt the

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service